Summary: A Taiwan-based company is unveiling two distinct smart sleep monitoring pads at CES 2025, one for people and one for pets. The iSleePad is designed for humans, utilizing contactless sensing technology to monitor vital signs such as heart rate, breathing, and sleep position. It also offers features like real-time alerts for bed exits and…
Summary: NLS Pharmaceutics and Kadimastem are progressing with their merger, having filed a registration statement with the US Securities and Exchange Commission (SEC). This merger aims to create a Nasdaq-traded biotechnology company. Kadimastem will become a wholly owned subsidiary of NLS, and after the transaction, Kadimastem shareholders will hold 85% of the newly merged company.…
Summary: Tonix Pharmaceuticals announced that the FDA has set a PDUFA goal date of Aug 15, 2025, for the decision on marketing approval for TNX-102 SL, a non-opioid treatment for fibromyalgia. This decision follows positive results from two phase 3 clinical trials, where TNX-102 SL demonstrated significant reductions in daily pain, along with improvements in…
Summary: The US FDA approved Zepbound (tirzepatide) on Dec 20, 2024, as a treatment for adults with moderate-to-severe obstructive sleep apnea (OSA) and obesity. The American Academy of Sleep Medicine (AASM) responded positively to the approval but cautioned that Zepbound is only effective for obesity-related OSA and may not cure the condition. The AASM emphasized…
Henry David Thoreau’s Walden might be one of the most lovely odes to a simpler, slower way of life. Thoreau, bone weary of city living, left everything and moved into the wilderness to enjoy solitude and work with his hands. He waxes eloquent about really attending to nature. After all, “a taste for the beautiful…